A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
NCT04016974 · Completed
Last updated 2026-05-28This study is testing how oral semaglutide tablets are absorbed and processed in the bodies of healthy Chinese adults.
What this study is testing ClinicalTrials.gov NCT04016974 ↗
Description as written by the study sponsor.
This study looks at the way a new medicine tablet called semaglutide moves in and throughout the body over time. It will also look at if the medicine is safe and the body can accept it. The new medicine is planned to treat diabetes. The aim of the study is to see how semaglutide tablets work in healthy people who are Chinese. Participants will either get oral semaglutide tablets or placebo (dummy) tablets - which treatment is decided by chance. The tablet form of semaglutide is a new medicine that cannot be prescribed. Doctors can prescribe semaglutide as an injection only. It is for the treatment of diabetes in some countries. Participants will get 1 tablet per day for 12 weeks (84 days). Participants will get 1 tablet a day to take with up to half a glass of water (maximum 120 mL). Participants must take the tablet first thing in the morning on an empty stomach (water is allowed until 2 hours before taking the tablet). After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After 30 minutes, they can have their first meal of the day and take any other medicines they may need, such as birth control tablets, routine vitamins and use of paracetamol at times.
Treatments tested
- Oral semaglutide Drug
Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
- Placebo Drug
Placebo tablets once daily throughout the treatment period (day 1 to 84)
| Main thing measured | AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Healthy Volunteers, Diabetes Mellitus, Type 2 |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04016974 ↗